NCT06876142 2026-03-19
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
Clinical Trials
5 trialsNCT00973804 2019-12-17
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00693433 2015-12-04
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00079456 2013-10-11
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00398515 2013-09-30
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed